16-0271-85

antibody from Invitrogen Antibodies

Targeting: CD27 S152, TNFRSF7, Tp55

Provider product page for 16-0271-85

Flow cytometry

Blocking/Neutralizing

Other assay

Antibody data

Antibody Data
Antigen structure
References [20]
Comments [0]
Validations
Flow cytometry [1]
Other assay [16]

Submit

Product number: 16-0271-85 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD27 Monoclonal Antibody (LG.7F9), Functional Grade, eBioscience™
Antibody type: Monoclonal
Antigen: Other
Description: Description: The LG.7F9 monoclonal antibody reacts with mouse CD27, a lymphocyte-specific member of the TNFR superfamily. CD27 is expressed by virtually all mature T cells and by a subpopulation of B cells, mainly memory B cells. In mouse, CD27 has been found on nearly all thymocytes excluding a population of CD46-CD8- precursors. CD27 binds to CD70 and, through this interaction, plays an important role in T cell-B cell interaction. It has been reported that triggering CD27 plays an important role in the maturation of CD4+ and CD8+ effector cells. LG.7F9 cross-reacts with human and rat CD27. Applications Reported: The LG.7F9 antibody has been reported for use in flow cytometric analysis. LG.7F9 has also been reported in blocking of ligand binding. Applications Tested: The LG.7F9 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.5 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 µm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.
Reactivity: Human, Mouse, Rat
Isotype: IgG
Antibody clone number: LG.7F9
Vial size: 500 µg
Concentration: 1 mg/mL
Storage: 4° C

CD27 protein structure - 16-0271-85 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIG 1 Lung CD19 + and CD27 + CD19 + cells at day 14 (A and B) and day 28 (C and D) postinfection. C57BL/6 mice were subcutaneously given 30 or 150 mug of anti-CD20 or isotype control antibody weekly. Three days after the first injection, all mice were inoculated with approximately 2 x 10 5 asci of P. murina inoculum. Fourteen or 28 days postinfection, the right upper and lower lung lobes were harvested, and single cells were prepared and stimulated with Pneumocystis (PC) antigen for 6 h followed by staining for cell surface markers and intracellular cytokine staining. For CD19 + and CD27 + CD19 + cells, 100,000 cells were acquired. One-way ANOVA and Tukey's multiple-comparison tests indicated that there were significant differences between anti-CD20 and isotype control antibody (ISO)-treated groups. Statistical significance is indicated as follows: ***, P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIG 6 Lung CD19 + and CD27 + CD19 + cells in secondary PC infection. All mice were inoculated with approximately 2 x 10 5 asci of P. murina inoculum. Six weeks later, the mice were subcutaneously given 30 or 150 mug of anti-CD20 or isotype control antibody weekly. Three days after the first injection, all mice were reinoculated with approximately 2 x 10 5 asci of P. murina inoculum. Fourteen days postinfection, the right upper and lower lung lobes were taken, and single cells were prepared and stimulated with PC antigen for 6 h for surface markers and intracellular cytokine staining. For both CD19 + and CD27 + CD19 + cells, 100,000 cells were acquired. One-way ANOVA and Tukey''s multiple-comparison tests indicated that there were significant differences between anti-CD20- and ISO-treated groups for CD19 + cells but not for CD27 + CD19 + cells. Statistical significance is indicated as follows: **, P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Phenotypic characterization of circulating B cell subsets in patients and HC. (A) Gated by CD19 + B cells, IgD + CD27 - NB, IgD + CD27 + USM B cells, IgD - CD27 + SM B cells, and IgD - CD27 - DN B cells were identified. The graphs are representative for HC and patients with different duration. Mean value of each B cell subset's percentage is shown in the quadrants. (B) Statistical graphs for comparison of CD19 + B cells' percentages between patient groups and HC. (C-E) Statistical graphs for distinct CD19 + B cells subsets between patients (SP, n = 48; SD, n = 23; LD, n = 25; FF, n = 33; LF, n = 15.) and HC (n = 25). Error bars represent mean+-SD. * P < 0.05, ** P < 0.01, *** P < 0.001, and NS P >= 0.05.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. Ontogenic timing influences gammadeltaT17 generation (A) Flow cytometry analysis of CD27 expression by gammadelta T cells in lymph nodes and lung of fetal-, neonatal-, or adult-induced RBPJ ind mice (left); right panels show percentages. (B) Flow cytometry analysis of IL-17 production by gammadelta T cells in lymph nodes and lung of mice as in (A) stimulated with PMA and ionomycin in vitro (left); right panels show percentages. Data are representative of three independent experiments. Data are presented as means +- standard deviation of three independent experiments. n = 3 mice per group. **p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way ANOVA). (C) Flow cytometry analysis of IL-17 production by gammadelta T cells in lung of control, fetal-, or adult-induced RBPJ ind mice after TDM challenge (top); bottom panels show percentages and numbers. Data are representative of three independent experiments. Data are presented as means +- standard deviation of three independent experiments. n = 6 mice for control; n = 3 mice per fetal- and adult-induced groups. Statistical analyses between groups are found in Figure S2D .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. ai-mAb-specific B cell sorting and sequencing (A) ai-mAbs fluorescently labeled with either phycoerythrin (PE) or allophycocyanin (APC) were used as bait to single-sort CD19 + CD20 + IgD + IgM + CD27 - B cells from PBMCs obtained from healthy, HIV-1-negative donors. VH and VL transcripts were recovered using RT-PCR, and amplicons were Sanger sequenced. (B and C) Frequencies of B cells expressing VH1-2 HC (B) and 5-aa CDRL3 (C) were compared between the different ai-mAbs. Frequencies in total unselected B cells were assessed as control. Data in (B) and (C) are presented as mean +- SD. All frequency data are given in Table S2 .

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Primary and secondary status of infection is linked to B cell/antibody readouts (A) NT 50 values of plasma collected at V1-V5 against DENV-1 (left column) or DENV-2 (right column) and for primary patients (top row, blue) or secondary patients (bottom row, red). Each set of connected dots represents 1 patient. (B) Binding of plasma antibodies from V1-V5. ELISA plates were coated with E protein (mostly monomeric, top row) or with UV-inactivated polyethylene glycol (PEG)-precipitated DENV (UV-DENV) (bottom row). E protein ELISA: line indicates the lowest dilution tested (1:500). Endpoint titers for the negative control plasma were 500. UV-DENV ELISA: line indicates the endpoint titer of the negative control plasma (2,500). Lowest dilution tested was 1:100. Primary: blue, secondary: red. Means +- SD are indicated. (C) Frequency of plasmablasts (CD27 + CD38 + ) among CD19 + B cells at V2 for primary and secondary patients. ***p = 0.0007, unpaired t test. Bars indicate the mean. (D) Frequencies of IgA + , IgM + , and IgG + (IgA - IgM - ) plasmablasts during acute disease, stratified according to hospitalization status. Bars indicate the median. (E) IgA expressed at the surface by the plasmablasts in (C); ****p < 0.0001, unpaired t test. Bars indicate the mean (F) Frequency of HLA-DR + cells among CD8 T cells at V2 in primary and secondary patients. **p = 0.002, unpaired t test. Bars indicate the mean. (G) Frequency of CXCR3 + Tfh (circle) or CXCR3 - Tfh (triangle) among CD

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. Dysregulation of Tcf7 /TCF1 in Id2 Delta/Delta NK cells. (A) Tcf7 mRNA in Ctrl and Id2 Delta/Delta NK cells by RNA-seq expressed as normalized reads. Data are from three biological replicates. Error bars represent SD. (B) TCF1 in CD27 + CD11b - NK cells from BM and spleen from Ctrl and Id2 Delta/Delta mice determined by flow cytometry. The MFI of TCF1 is indicated for Ctrl (black) and Id2 Delta/Delta (blue; n = 4 for BM and n = 3 for spleen; data are from independent experiments). (C and D) Summary of relative TCF1 MFI from BM and spleen. MFI of Ctrl NK cells was set as 1 in each experiment. (E) CD49b + -enriched BM NK cells were cultured in IL-15 (20 ng/ml) for 6 d before flow cytometry analysis for TCF1 in NK1.1 + CD49b + cells. The MFI for TCF1 in Ctrl (black) and Id2 Delta/Delta (blue) is shown. (F) Summary of relative TCF1 MFI in IL-15-cultured NK cells. MFI of Ctrl NK cells was set as 1 in each experiment ( n = 4; data are from independent experiments). Error bars represent SEM (C, D, and F). (G) Chromatin accessibility surrounding the Tcf7 gene as determined by ATAC-seq on CD27 + CD11b - NK cells (). Ctrl (black) and ID2-deficient (blue) NK cells. (H) Enhanced view of the indicated region of the Tcf7 intron showing increased chromatin accessibility in ID2-deficient CD27 + CD11b - NK cells. (I) The same region as in H but showing nucleosome depletion. (J) E protein ChIP was performed on chromatin isolated from Ctrl or Id2 Delta/Delta BM NK cells and amplified

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. TCF1 deficiency restores NK cell surface receptor expression in Id2 Delta/Delta NK cells. (A) Flow cytometry plots of different receptors on NK cells of BM (top) and spleen (Sp; bottom) from Id2 Delta/Delta Tcf7 Delta/Delta (red), Id2 Delta/Delta (blue), and Ctrl (black) mice. Numbers are the percentage of cells in the indicated gates. Data represent three to six independent experiments ( n = 3-6 for each group). (B) Summary of data shown in A. MFI of Ctrl NK cells was set as 1 in each experiment for CD27 and IL-4Ralpha. Error bars represent SEM. Statistical significance was determined by one-way ANOVA with Tukey's multiple comparisons test. *, P < 0.05; **, P < 0.01; ***, P < 0.005; ****, P < 0.001. (C and E) BM and spleen tSNE analysis showing expression of CD27 or CD11b on Ctrl NK1.1 + CD49b + NK cells and the overlay of the two markers. Data are representative of two experiments. (D and F) BM and spleen tSNE analysis on NK1.1 + CD49b + NK cells for each of the indicated genotypes. Plots were generated using surface receptors (NK1.1, CD49b, CD27, CD11b, CD49a, KLRG1, CD146, SLAMF6, CD226, IL4Ra, and CXCR3). Data are representative of two experiments.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure S2. Altered gene expression in Tcf7 Delta/Delta BM NK cells. (A) Sequence of the intronic region of Tcf7 that shows increased accessibility in ID2-deficient BM CD27 + CD11b - NK cells. (B) Schematic representation of the overlap between regions with altered chromatin accessibility in ID2-deficient CD27 + CD11b - NK cells by ATAC-seq and TCF1 binding sites in CD8 T cells determined by ChIP-seq (Gene Expression Omnibus accession no. GSE73239 ). Regions with increased accessibility by ATAC-seq are shown in yellow, decreased accessibility in peach, and no change in orange. TCF1 binding sites are significantly enriched in ATAC-seq regions that gain accessibility in ID2-deficient cells. P < 1.846 10-66 (Fisher's exact test). (C) Volcano plot showing Log2FC versus adj. P values for RNA-seq data from Tcf7 Delta/Delta and Ctrl NK cells. Data were generated from three biological replicates. (D) GSEA for Ctrl versus Tcf7 Delta/Delta NK cell RNA expression. (E) Table showing differentially expressed genes from RNA-seq data shown in C . (F) Flow cytometry plots of different proteins on NK cells of spleen from Tcf7 Delta/Delta and Ctrl mice ( n = 3-4 for each group from independent experiments). (G) Summary of the data in F. Error bars represent SEM. Statistical significance was determined by two-tailed unpaired t test. *, P < 0.05; **, P < 0.01. FDR, false discovery rate; NES, normalized enrichment score.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3. Pik3cd E1020K/+ mice fail to develop a robust T CM population (A-F) Viable CD8 + splenocytes from mice infected with LCMV Armstrong (n = 2, 4-5/group/time point). (A-C) NP396-specific CD8 + cells day 15 p.i. (A) CD127 and KLRG1 expression (left: representative staining; right: %KLRG1 + CD127 - ). (B) Representative histogram of CD27 (top) and CD127 (bottom). (C) GzmB and TCF1 staining. Middle: TCF1 MFI; right: GzmB MFI. (D-F) NP396-specific CD8 + cells day 58 p.i. (D) CD44 and CD62L staining. Representative flow (left), % CD44 hi CD62L lo cells (right). (E) CD127 histograms: CD44 hi CD62L lo (top) and CD44 hi CD62L + (bottom). (F) TCF1 MFI. (G) TCF1 staining of allo-reactive CD8 + cells from healthy controls and patients with APDS (n = 2, representative histogram). (H-L) Mice were infected with X31 and challenged with PR8 (n = 2, 3-5 mice/genotype/time point). (H) Infection outline. (I) PA224-specific CD8 + cell numbers. (J) IFN-gamma and TNF-alpha from day 8 cells stimulated with either PA 224-233 (left) or anti-CD3 plus anti-CD28 (right). (K) NP366-specific CD8 + T cell numbers. (L) IFN-gamma and TNF-alpha from day 35 cells stimulated with either NP 366-374 (left) or anti-CD3 plus anti-CD28 (right). (M-O) OT-1 cells were transferred into congenic hosts, infected with influenza X31-OVA and challenged with PR8-OVA (n = 2, 3 mice/genotype/time point). (M) Outline. (N) Viable OT-1 cell numbers. (O) TCF1 and GzmB expression in OT-1 cells on day 35. Representative exper

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Dynamic Tsc1 expression following IL-15 stimulation. ( a - c ) Quantitative reverse transcription-PCR (RT-PCR) analysis of the indicated genes in sorted CD3 - NK1.1 + cells from the spleen of WT mice before and after stimulation with 25 ng ml -1 IL-15 for 18 h ( a ), various concentration of IL-15 ( b ), or at the indicated time points ( c ). ( d ) Intracellular phosphorylated S6 in sorted NK cells after stimulation with 25 ng ml -1 IL-15 was detected by flow cytometry at the indicated time points, and the mean fluorescence intensity was calculated. ( e ) Tsc1 messenger RNA (mRNA) expression was analysed by quantitative RT-PCR in sorted CD3 - NK1.1 + cells after stimulation with 25 ng ml -1 IL-15 for 18 h in the presence of DMSO or rapamycin (10 nM). ( f ) Analysis of Tsc1 mRNA expression in sorted T, B and NK cells by quantitative PCR. (g) Analysis of Tsc1 mRNA expression in CLP, NKp and immature NK cells (iNK), and NK cell subsets, including CD27 - CD11b - (DN), CD27 + CD11b - (CD27 SP), CD27 + CD11b + (DP) and CD27 - CD11b + (CD11b SP), by quantitative PCR. The results were normalized to beta- actin ( f , g ) or are presented relative to expression in untreated cells, which was set as 1 ( a - c , e ). Value represent mean+-s.d. * P